Heme oxygenase-1 (HO-1) is a major anti-inflammatory enzyme and a key regulator that induces immune tolerance through affecting the differentiation of dendritic cells. The aim of this study is to determine whether the combination of 5-aminolevulinic acid (ALA) and iron induces HO-1 expression in healthy human peripheral blood mononuclear cells (PBMC).
Introduction
Heme oxygenase-1 (HO-1) is a heme-catabolizing enzyme which is induced by oxidative stress or other stimuli. HO-1 degrades heme into biliverdin, carbon monoxide (CO), and iron, and biliverdin is immediately reduced and turned into bilirubin by biliverdin reductase. As biliverdin/bilirubin and CO both have anti-oxidative functions, HO-1 is deemed to be a promising drug target (Ryter et al., 2006) . Furthermore, many studies have reported a new role for HO-1 as a switch in immature dendritic cells (DCs) causing them to differentiate into tolerogenic DCs (Al-Huseini et al., 2014; Lee et al., 2007; Moreau et al., 2009; Remy et al., 2009; Schumacher et al., 2012) . Tolerogenic DCs induce the proliferation / differentiation of regulatory T cells, a T cell subset essential for establishing immune tolerance by suppressing the conventional T cell response. Therefore, HO-1 expression in the DCs could alleviate unwanted immune responses such as the rejection of allogeneic organs after transplantation, autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis, and other inflammatory diseases such as cisplatin-induced nephrotoxicity.
Hemin, the Fe-oxidized stable form of heme, is a strong HO-1 inducer (Bharucha et al., 2010; Doberer et al., 2010; Thomas et al., 2016) and there are several on-going clinical trials focusing on its HO-1-inducing ability. However, the repetitive clinical use of hemin is difficult because of its poor oral absorbability and the cellular uptake route via TLR4, which activates the NF-κB inflammatory pathway (Lin et al., 2012) . Although numerous compounds for oral administration such as aspirin, statins, probucol, losartan, rapamycin, curcumin, resveratrol, and the multiple sclerosis drug, dimethyl fumarate, are proven to increase HO-1 expression in vitro or in animal studies (Abraham and Kappas, 2008; Lin et al., 2011) , there are no human study results or only negative results (Bharucha et al., 2014) with the exception of the finding that the decreased HO-1 level in tobacco smokers was restored by two weeks' melatonin administration (Wang et al., 2016) .
We previously reported that 5-aminolevulinic acid, a precursor of heme, in combination with divalent iron (Sodium Ferrous Citrate: SFC) is also able to induce HO-1 in vitro through the phosphorylation of ERK / p38 and the nuclear translocation of a transcription factor Nrf2, as well as the depletion of a repressor protein BACH1 binding to the promoter site of HO-1 (Nishio et al., 2014) . Furthermore, ALA+SFC effectively suppressed ischemia / reperfusion injury of the kidneys and established immune tolerance in cardiac allografts in mice (Hou et al., 2013 (Hou et al., , 2015 .
However, it is not known whether ALA+SFC can induce HO-1 in humans in any tissue so far. Here we report that a single oral administration of ALA+SFC is able to induce HO-1 in the peripheral blood of healthy volunteers.
Materials and methods

Study design
This study was a single-center, open label, non-placebo, prospective intervention study with the aim of determining whether HO-1 in PBMCs and DCs can be upregulated by the combination of ALA and SFC. It was conducted from May 2016 to December 2016. The study was approved by the institutional review board of P-One Clinic, Keikokai Medical Corporation, and the National Center for Child Health and Development.
This study is registered in the Japan Pharmaceutical Information Center (JAPIC) database (JapicCTI-163281). This study consists of three parts: Study A, aimed at determining time course changes in HO-1 expression in peripheral blood mononuclear cells (PBMCs) and DCs after a single administration of ALA+SFC; Study B, aimed at determining the dose dependency of ALA+SFC and the promotive effect of the co-administration of SFC using three doses of ALA+SFC, three doses of ALA-alone, and one dose of SFC-alone; and Study C, aimed at determining the effect of the repetitive administration of ALA+SFC.
Study A: ALA hydrochloride 600 mg and SFC 942 mg were administered to five healthy male volunteers only once. Blood was taken just prior to administration (0 h), 1, 2, 3, 4, 6, 8, 12, 16 , and 24 h after administration to measure the HO-1 of PBMCs.
The time point marking the highest of ten PBMC HO-1 levels was determined. The HO-1 level in the DCs was also determined by flow cytometry.
Study B:
In Group 1-3, ALA hydrochloride 150, 300, and 600 mg and SFC 235, 471, and 942 mg, respectively, were administered as Course I. In Group 4, SFC 942 mg was administered as Course I. Thereafter, ALA hydrochloride 150, 300, and 600 mg were administered with six-day intervals as Course II. Blood was taken just prior to administration (0 h) or at 8 h (as based on the results of Study A) after administration to measure the HO-1 of the PBMCs. Each group consisted of five healthy males.
The following was measured: 1. Change in HO-1 level from baseline after administration of ALA-alone; 2. Change in HO-1 level from baseline after the administration of the ALA and SFC combination; 3. Difference in the levels of HO-1 increase after the administration of ALA alone and the combination of ALA and SFC.
Study C: ALA hydrochloride 600 mg and SFC 942 mg were administered to five healthy male volunteers once daily for three days. Blood was taken just prior to administration or at 8 h after administration daily to measure the HO-1 of the PBMCs. Changes in the HO-1 level after 8 h each day were measured.
Study population
Healthy male volunteers were recruited by P-One Clinic, Keikokai Medical Corporation. The ethnicity of the volunteers was not ascertained. After written informed consent was obtained, the eligibility of the subjects was checked by screening tests within 28 days of administration. Whenever it was necessary to do the tests again or to perform additional tests, the reasons were explained to the subjects and their consent was obtained prior to testing. The subjects who were determined to be eligible were admitted to the clinic on the day prior to the commencement of the study and their eligibility was confirmed by pre-administration tests.
The inclusion criteria were as follows:
1) Those who agreed of their own free will to participate in the study and submitted their written informed consent. 2) Healthy males between the age of 20 and 45 years on the day of enrollment. 3) Those who did not smoke six months before administering the test drug. 4) Those with a body weight at the time of screening of more than 50 kg and a body mass index (BMI) > 18.5 kg/m 2 and < 25 kg/m 2 .
The exclusion criteria were as follows:
1) Those with any clinically significant cardiovascular, hepatic, renal, gastrointestinal, endocrine, hematological, respiratory, or neurological/psychiatric disorder. 2) Those with a history of any of the above disorders, who were deemed by the medical director to be inappropriate as subjects. Those with seasonal allergic disorder were included if the medical director determined it was unlikely to occur during the study period. 3) Those with hypersensitivity to porphyrin and related substances, or who suffered from porphyria. 4) Those with allergies, or with a history of allergy, to drugs (prescription or non-prescription) and food items. 5) Those addicted to alcohol or drugs. 6) Those positive for immunological tests (HBs antigen, HCV antibody, serological reaction of syphilis, or HIV antigen/antibody) 7) Those with a clinically problematic abnormality found at screening, on the day prior to or immediately before administration. 8) Those with a history of gastrointestinal surgery such as gastric resection, gastroenteroanastomosis or enterectomy. 9) Those who received drugs or foods during the periods described below. Especially close attention was paid to photosensitivity-inducing drugs such as tetracycline antibiotic, new quinolone antimicrobial agent, sulphonamide drugs, hypericin (St. John's wort extract), and St. John's wort-containing foods.
-Prescription / non-prescription drugs and vitamin supplements: 14 days before administration of the test drug (artificial tears for contact lens were excluded) -Alcohol: three days before administration of the test drug 10) Those scheduled to see doctor during the study period. 11) Those who participated in other clinical trials and received experimental drugs three months before receiving the test drug. 12) Those from whom 400 ml and 200 ml of whole blood was collected three months and one month, respectively, before receiving the test drug or who experienced plasmapheresis / platelet apheresis two weeks before receiving the test drug. 13) Those who were unwilling to or unable to obey the instructions for subject management determined in the protocol. 14) Those determined by the investigators to be inappropriate for participation.
Drug administration and subject management
Five-aminolevulinic acid hydrochloride (neo ALA Co., Ltd) and sodium ferrous citrate (Eisai Food & Chemical Co., Ltd; provided as Sanferol®) were administered orally. Each drug was enclosed in an oral bag-type wafer and swallowed with an appropriate amount of water. ALA was first given, followed immediately by SFC.
Administration of other drugs was prohibited unless deemed necessary by the investigators.
The subjects were admitted into the clinic one day prior to the administration of the drugs and remained in hospital until completing the observation / tests: on the day after the administration (Study A); on the day after each Course (Study B); or four days after the administration (Study C).
Study endpoint
The primary endpoint of each study was as follows: The HO-1 protein levels were determined by flow cytometry and enzyme-linked immunosorbent assay (ELISA), and the HO-1 mRNA levels were determined by quantitative reverse transcription PCR.
In Study A, the peak point of the total bilirubin and Protoporphyrin IX (PpIX), a heme precursor, level was determined as the secondary endpoints.
All the adverse events and side effects in the studies were recorded.
Sample size and statistical analysis
As this was an exploratory trial, we did not determine the number of subjects based on statistical methods which take the significance level and statistical power into consideration. The sample size was determined based on practical consideration.
The mean and S.D. were used to describe variables of interest. Changes from baseline (0 h) were assessed by use of the two-tailed paired Student's t-test, and intergroup differences were assessed by use of the two-tailed independent Student's t-test. P < 0.05 was considered statistically significant.
Blood collection and total bilirubin/ protoporphyrin measurement
For the PBMC / DC collection, 8 ml of blood was taken using Vacutainer® CPT Mononuclear Cell Preparation Tube -Sodium Heparin (BD Bioscience) as instructed in the manufacturer's manual.
For the bilirubin measurement, sera from 3 ml of whole blood were collected with VENOJECT II Evacuated Tube (Terumo Corporation). Total bilirubin was measured using the vanadate oxidation method.
PpIX was measured from the remaining plasma in the CPT tube. First, 0.1 ml of plasma was vigorously agitated for 30 s with 0.01 ml of 50% v/v acetic acid and 0.3 ml of N,N-dimethylformamide-2-propanol (DMF-IPA) solution (100:1 by vol.) and centrifuged at 20,000 ×g for 5 min at 4°C to collect the supernatant. The precipitate was extracted with 0.15 ml of DMF-IPA solution by repeating the same procedures as above. The two batches of supernatant were mixed and analyzed with an HPLC system using a Capcell Pak C18 UG120 column (5 µm, 4.6 × 150 mm, Shiseido, Tokyo, Japan), Acetonitrile: 10 mM tetrabutylammonium hydroxide solution (pH 7.5) = 7:3 (v/v) (flow rate, 1.0 ml/min; elution temperature, 40°C), and fluorescence detector (Ex. 400 nm, Em. 630 nm).
Collected PBMCs were stained with the following antibodies to sort the DCs: CD11c-PE-Dazzle594, CD123-PE/Cy7, HLA-DR-APC/Cy7, and Lineage Cocktail (CD3/14/16/19/20/56)-APC (all antibodies were purchased from BioLegend Inc.). For isotype control, the following was used: mouse IgG1-PE/Dazzle594, mouse IgG2a-APC/Cy7, mouse IgG1-PE/Cy7, mouse IgG1-APC, and mouse IgG2b-APC (purchased from BioLegend Inc.). The stained cells were fixed and permeabilized with Foxp3 fixation/permeabilization concentrate and diluent (Thermo Fisher Scientific) and then stained with HO-1-PE antibody (Abcam plc.). 
Flow cytometry
ELISA
For ELISA, PBMCs were cryopreserved and thawed only once. The levels of HO-1 in PBMCs were detected with HO-1 (Human) ELISA kit (ENZO Life Sciences) according to the manufacturer's instructions.
Real time quantitative PCR
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN Inc.) following the manufacturer's instructions with DNase digestion steps. Total RNA was reverse transcribed into cDNA using the PrimeScript RT Master Mix (Perfect Real Time) (TaKaRa Inc.) according to the manufacturer's instructions. The reactions were performed using the KAPA SYBR Fast qPCR kit ABI Prism (NIPPON Genetics Co., Ltd.) in a 7900HT Fast Real-Time PCR System (Applied Biosystems Inc.). The PCR conditions were as follows: 50 ℃ for 2 min, 95 ℃ for 2 min, 45 cycles at 95 ℃ for 5 s and 60 ℃ for 30 s. The HO-1 gene expression level relative to the internal control gene (18 S) was calculated by the comparative Ct method. The primer sequences were as follows: HO-1 forward, 5′-CAGGGTGACAGAAGAGGCTAAGAC-3′ and reverse, 5′-TTGTGTTC CTCTGTCAGCATCAC-3′, 18 S forward, 5′-ATGAGTCCACTTTAAATCC TTTAACGA-3′ and reverse, 5′-CTTTAATATACGCTATTGGAGCTG GAA-3′. (Fig. 1A-C) In Study A, consent was obtained from 15 volunteers after the purpose of the study was explained prior to the intervention. The number of registered volunteers was five out of 15, since one out of ten volunteers met the exclusion criteria, six volunteers rescinded their consent, and three individuals were registered as back-up volunteers.
Results
Study population
All five subjects received the test drugs and completed participation. In Study B, consent was obtained from 61 volunteers after the purpose of the study was explained prior to the intervention. The number of registered volunteers was 20 out of 61, since three out of 41 volunteers met the exclusion criteria, two volunteers rescinded their consent, 32 volunteers were not allocated as we reached the target number, and four individuals were registered as back-up volunteers.
All 20 subjects received the test drugs and completed participation. In Study C, consent was obtained from 17 volunteers after the study was explained prior to the intervention. The number of registered volunteers was five out of 17, since four out of 12 volunteers met the exclusion criteria, one volunteer rescinded consent, five volunteers were not allocated as we reached the target number, and two individuals were registered as back-up volunteers.
All five subjects received the test drug and completed the study. The characteristics of the subjects are shown in Table 1 . Data from all subjects who received the test drug were analyzed. Safety analysis was conducted for the same subjects.
Safety
In Studies A and B, no adverse effects were observed. In Study C, mild headache and moderate nausea occurred in one subject who received ALA 600 mg and SFC 942 mg (3.3% of all subjects participated in three studies). These symptoms ceased without treatment. Of these adverse effects, nausea was found to be a side effect. No severe adverse effects including death were observed in any of the studies.
Blood tests were conducted at screening, on the day prior to drug administration, and at 24 h after the last administration. The following items were measured: white blood cell, neutrophil, lymphocyte, monocyte, eosinophil, basophil, and red blood cell count; hemoglobin, hematocrit, platelet count, total protein, total bilirubin, AST, ALT, ALP, LDH, γ-GTP, total cholesterol, uric acid, BUN, creatinine, CK, glucose, Na, K, Cl, and C-Reactive Protein (CRP) as an inflammation marker. The vital signs (body temperature, systolic blood pressure, diastolic blood pressure and pulse rate) were also assessed.
In all three Studies, there were no clinically problematic changes in all items.
HO-1 upregulation with ALA and SFC and kinetics of ALA derivatives
Study A As shown in Fig. 2A , the time-course the HO-1 protein expression level of PBMC after administration of ALA 600 mg and SFC 942 mg was measured with ELISA at the 0, 1, 2, 3, 4, 6, 8, 12, 16, and 24 h. Although there was no significant change, a clear, bell-shaped curve was observed. The peak was observed at 6 h and 8 h.
PBMC protein expression level measured with flow cytometry showed upregulation of HO-1 protein (Fig. 2B ). An increase in HO-1 in plasmacytoid DC and an increasing tendency in myeloid DC was also observed using flow cytometry.
An increasing tendency and a peak at 6 h were observed in the mRNA expression although the change was not significant (Fig. 2C) . Two samples at 2 h and one sample at 4 and 24 h were omitted since the internal control value was abnormal.
Plasma PpIX was measured in Study A. PpIX had significantly increased after drug administration and peaked at 6 h (Fig. 2D ).
The serum total bilirubin level was also measured in Study A. Unexpectedly, the bilirubin level had decreased at 8-16 h after administration and recovered at 24 h (Fig. 2E) .
The peak HO-1 protein level was measured as 8 h as the lowest pvalue was ascertained at 8 h in the ELISA data despite the fact that the average level was slightly higher at 6 h.
Study B ALA and SFC were administered at the following doses: ALA 150 mg / SFC 235 mg, ALA 300 mg / SFC 471 mg, and ALA 600 mg / SFC 942 mg, for Groups 1-3, respectively.
Consecutively ALA alone was administered at the dose of 150 mg, 300 mg, and 600 mg to Groups 1-3, respectively, 7 days after previous co-administration.
As shown in Fig. 3A , the ELISA measurement showed no significant difference in HO-1 expression between 0 h and 8 h after administration under any condition. One sample at 0 h from Group 2 during Course I, one sample at 0 h from Group 3 at Course I, one sample at 8 h from Group 3 at Course I, and one sample at 0 h from Group 4 were omitted due to the small amount of protein in the samples. Although one sample at 0 h from Group 1 during Couse I and one sample at 8 h from Group 4 contained a slightly smaller amount of protein, the data were included.
The relative rate of increase in HO-1 with ELISA is shown in Fig. 3B . Although not significant, a consistent increasing tendency in the HO-1 amount for all dosages was observed while no increase in HO-1 was observed when ALA alone was administered. A comparison of the ALA 600 mg + SFC 942 mg group (Group 3, Course I) with the SFC 942 mgalone group (Group 4) showed that the HO-1 expression of the former was significantly higher.
Study C Subjects were given ALA 600 mg + SFC 942 mg per day for three days. In ELISA, there was slight increasing tendency in the HO-1 level (Fig. 4A ). Although one sample at 0 h and 8 h on Day 2 contained a slightly smaller amount of sample protein, the data were included.
As the HO-1 levels before administration and at 8 h after administration of ALA 600 mg + SFC 942 mg were examined for studies A to C, we integrated the data and compared the results for the ALA 600 mgalone group and the SFC 942 mg-alone group in Study B. The results are shown in Fig. 5 . Whereas there was no significant increase between 0 h and 8 h after administration of ALA 600 mg + SFC 942 mg in each study, the integrated data showed a significant increase between 0 h and 8 h.
Discussion
Among healthy male subjects, 5-aminolevulinic acid in combination with sodium ferrous citrate was administered to induce heme oxygenase-1(HO-1) in the peripheral blood mononuclear cells. We observed a significant upregulation of HO-1 in the group which received ALA 600 mg and SFC 942 mg compared to the baseline level (Fig. 5) . The peak HO-1 level was measured at 6-8 h after administration ( Fig. 2A) .
Although a significant increase in HO-1 was observed, some subjects were apparently non-reactive, possibly because of the polymorphism of the promoter region of the HO-1 gene. It is known that the longer (GT) n dinucleotide repeating in the promoter region of HO-1 negatively affects the inducibility of HO-1 (Yamada et al., 2000) . It is also possible that that ALA non-responders have longer (GT) n repeats.
HO-1 induction with ALA+SFC is thought to be due to the upregulation of heme synthesis as evidenced by previous reports showing that ALA+SFC transiently increased the intracellular heme amount (Nishio et al., 2014) and that hemin administration promoted Nrf2 nuclear translocation and BACH1 dissociation leading to HO-1 induction, which was also observed in a ALA+SFC study in vitro (Nakaso et al., 2003; Nishio et al., 2014; Ogawa et al., 2001; Saito et al., 2017) .
Heme is transported into the nucleus via cytosol (Tsiftsoglou et al., 2006) , while Nrf2 translocation by treatment with heme is due to its function as an reactive oxygen species producer (Ray et al., 2012) . Although we cannot deny that HO-1 induction with ALA+SFC is also attributed to heme-derived reactive oxygen species, the fact ALA+SFC-derived heme is produced inside the mitochondria suggests that reactive oxygen species involvement is much smaller considering that the mitochondria, the main site of reactive oxygen species production, must have higher reactive oxygen species -controlling ability. It also suggests that heme itself, rather than heme-derived reactive oxygen species, has the ability to induce Nrf2 translocation via as yet an unknown mechanism. We need further investigation to determine whether ALA+SFC can induce HO-1 without a reactive oxygen species increase to prove this hypothesis.
We also assessed the dose dependency of ALA +SFC and the effect of the co-administration of SFC. No clear dose dependency was observed but ALA alone tended to have no effect, and the combination of ALA and SFC was necessary to induce HO-1 (Fig. 3B) . This result was consistent with the findings of previous animal and in vitro study reports showing that the addition of iron to the ALA was important for inducing HO-1 and subsequent beneficial effects including induction of the immune checkpoint PD-L1 in DC (Hou et al., 2013 (Hou et al., , 2015 Nishio et al., 2014) , as well as other effects of ALA+SFC possibly due to the upregulation of heme synthesis Suzuki et al., 2015) .
There is an apparent contradiction in that cells in healthy males which generally have abundant stores of iron in the form of ferritin need additional iron to upregulate HO-1. We hypothesize that the surge in exogenous ALA-derived heme precursors in the mitochondria transiently requires an abundant mitochondrial labile iron pool which immediately rises by exposure to ferrous iron (Shvartsman et al., 2007) rather than to iron stored in cytosolic ferritin.
Subjects to whom ALA alone was administered might have generated heme more slowly due to the shortage of mitochondrial labile iron, and HO-2, constantly expressing heme oxygenase, might be sufficient to degenerate exogenous ALA-derived heme.
We measured a fluctuation in the HO-1 level during the 3-day, repetitive administration of ALA 600 mg and SFC 942 mg. Obvious accumulation of HO-1 protein within 3 days was not observed although a slight tendency to accumulation was seen in the mRNA level (Fig. 4B) .
Given that ALA+SFC-induced HO-1 returns to the basal level in 24 h, daily administration of ALA+SFC might be needed to sustain HO-1 level, while the intravenous administration of heme arginate (hemin supplemented with arginine) maintains HO-1 upregulation for more than 48 h (Bharucha et al., 2010; Doberer et al., 2010) . The average serum total bilirubin level in a healthy individual is approximately 23 mg / body while ALA hydrochloride 600 mg theoretically produces 261.6 mg of bilirubin (Davy and Seals, 1994; Zucker et al., 2004) . Therefore, the serum total bilirubin increase was expected as an alternative marker of HO-1 upregulation. However, on the contrary to the hypothesis, we could not find any increase in bilirubin within 24 h in Study A (Fig. 2E) .
This result may suggest that a considerable amount of ALA is metabolized into bilirubin in the liver and directly excreted from the body without going through the blood vessels. This is consistent with our unpublished study in which radioisotope ALA given to rats showed many external ALA-derived compounds accumulating in the liver and kidney.
As total bilirubin is known to fluctuate throughout the day and to be lower during the night (Larsson et al., 2009) , the significant decrease at 8-16 h could be explained as an ordinary phenomenon unrelated to drug administration although a placebo group is needed to prove this.
We observed HO-1 upregulation after ALA+SFC administration in the peripheral blood DCs. Chora et al. showed that HO-1 induction in the CD11c positive myeloid DCs in the spleen was crucial to suppressing antigen-induced T cell proliferation, which is possibly mediated by regulatory T cells (Chora Â et al., 2007) . Hence HO-1 induction in CD11c positive DCs with ALA+SFC suggests that the combination of ALA+SFC is a promising candidate for a tolerance-inducing drug. The reason why or how HO-1 induces tolerance is not fully known. However, several reports showed that molecules involved in immune tolerance such as PD-L1 and indoleamine 2,3-dioxygenase (IDO) are regulated by HO-1 (Jung et al., 2010; Wong et al., 2016) . In addition, there are also some reports that HO-1 induces the STAT-3 pathway, and STAT-3 is regarded as an inducer of PD-L1 and IDO (Ke et al., 2012; Sun et al., 2009; Wolfle et al., 2011) . Taken together, we propose that ALA+SFC can induce tolerance via STAT-3 (Fig. 6) .
One limitation of the present study is that we did not determine whether CD11c positive DCs in the lymphoid/non-lymphoid tissue are also upregulated by ALA+SFC by tissue biopsy due to its highly invasive nature. While the CD11c positive DCs in the blood are thought to . Integrated data for 8 h/0 h relative ratio of PBMC HO-1 expression after ALA 600 mg administration measured by ELISA. Data from ALA 600 mg group in Studies A, B, and C were integrated. All data are expressed as the mean ± S.D. *P < 0.05: two-sided paired Student's t-test. †P < 0.05: two sided independent Student's t-test.
be precursors of DCs / immature DCs and mature DCs in lymphoid/nonlymphoid tissue (Lipscomb and Masten, 2002; Raker et al., 2015) , it is still not known whether inducing HO-1 in the blood DCs is more important than inducing it in tissue DCs. Further investigation of the inability of antigen-specific CTL proliferation with ALA+SFC is needed to determine whether ALA+SFC actually induce immune tolerance in the human body.
There is no evidence that HO-1 is involved in tolerogenic maturation of CD123 + plasmacytoid DCs. Although the biological significance of HO-1 upregulation in pDCs should be confirmed in the future, this is the first report of HO-1 in pDCs being upregulated by ALA+SFC. Although the injection of heme 3 mg/kg in the form of heme arginate has been proven to increase the HO-1 level more highly than ALA+SFC, the use of heme arginate is limited because it is an injectable drug and its leakage into tissue causes necrosis (Edmunds et al., 2014) . Based on clinical evidence, ALA+SFC is at present the only pragmatic HO-1 inducer for treatment that does not require intensive attention.
In conclusion, ALA, which is already approved in several countries as a cancer diagnosis agent, may be useful as a novel therapeutic drug for diseases stemming from an unwanted immune response such as an autoimmune disease or for the rejection response to transplanted organs. Fig. 6 . Schematic image of the molecular pathway induced by ALA+SFC in DC. ALA+SFC turn into heme, and heme induces transcription factor Nrf2 while promoting degradation of the repressor BACH1. HO-1 is positively regulated by Nrf2 and suppressed by BACH1. Induction of HO-1 causes activation of STAT-3 pathway, and leading to increased expression of IDO and PD-L1, the key factors to induce immune tolerance.
